David Carbone, MD, PhD, from Ohio State University, Columbus, OH discusses the increasingly important role of immunotherapy in the treatment of lung cancer. Dr Carbone explains the potential advantages of using immunotherapy in the treatment of lung cancer as both single and combination therapies to improve treatment efficacy. Using biomarkers, it is possible to identify patients who will benefit more from immunotherapy as a first-line treatment. Dr Carbone uses the example of patients with high PD-L1, who react better to immunotherapy as a first-line treatment compared to chemotherapy as a first-line treatment. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.

свернуть